Search results
Showing 1351 to 1365 of 2026 results for nice guidelines
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)
This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.
This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)]
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
This guidance has been updated and replaced by NICE guideline NG192 and the recommendations on multiple pregnancy have been updated and replaced by NICE guideline NG137.
Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on mepolizumab (Nucala) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.
How we collect and use your personal information, and your rights under data protection legislation.
Temperature control to improve neurological outcomes after cardiac arrest (HTG710)
Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).
View recommendations for HTG710Show all sections
Immunisations: reducing differences in uptake in under 19s (PH21)
This guideline has been replaced by NICE guideline NG218.